key: cord-0898828-0hc14idt
authors: Miersch, Shane; Li, Zhijie; Saberianfar, Reza; Ustav, Mart; Brett Case, James; Blazer, Levi; Chen, Chao; Ye, Wei; Pavlenco, Alevtina; Gorelik, Maryna; Garcia Perez, Julia; Subramania, Suryasree; Singh, Serena; Ploder, Lynda; Ganaie, Safder; Chen, Rita E.; Leung, Daisy W.; Pandolfi, Pier Paolo; Novelli, Giuseppe; Matusali, Giulia; Colavita, Francesca; Capobianchi, Maria R.; Jain, Suresh; Gupta, J. B.; Amarasinghe, Gaya K.; Diamond, Michael S.; Rini, James; Sidhu, Sachdev S.
title: Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations
date: 2021-07-28
journal: J Mol Biol
DOI: 10.1016/j.jmb.2021.167177
sha: 2a667a391c3f728d2ea03a40c6d4c81989ad87c6
doc_id: 898828
cord_uid: 0hc14idt

Neutralizing antibodies (nAbs) hold promise as therapeutics against COVID-19. Here, we describe protein engineering and modular design principles that have led to the development of synthetic bivalent and tetravalent nAbs against SARS-CoV-2. The best nAb targets the host receptor binding site of the viral S-protein and tetravalent versions block entry with a potency exceeding bivalent nAbs by an order of magnitude. Structural studies show that both the bivalent and tetravalent nAbs can make multivalent interactions with a single S-protein trimer, consistent with the avidity and potency of these molecules. Significantly, we show that the tetravalent nAbs show increased tolerance to potential virus escape mutants and an emerging variant of concern. Bivalent and tetravalent nAbs can be produced at large-scale and are as stable and specific as approved antibody drugs. Our results provide a general framework for enhancing antiviral therapies against COVID-19 and related viral threats, and our strategy can be applied to virtually any antibody drug.

As of July 17, 2021, the ongoing COVID-19 viral pandemic has tallied more than 188,000,000 confirmed cases and caused over 4,000,000 deaths (www.who.int). Moreover, the highly infectious nature of the disease has imposed severe global economic hardship due to the need for social distancing and lockdown measures. A number of repurposed drugs have shown only limited or uncertain efficacy against COVID-19 [1, 2] . Although licensed vaccines are now being applied [3] , their effectiveness across demographics, availability worldwide, and resistance to adoption by the public remains an unknown. Almost certainly, COVID-19 will remain a serious human health concern for the foreseeable future and there is an urgent need for the development of therapeutics capable of treating patients and those at high risk for infection and/or with a poor prognosis.

Several lines of evidence suggest that SARS-CoV-2 neutralizing antibodies (nAbs) that bind directly to the virus spike glycoprotein and inhibit entry into host cells have therapeutic potential. First, many infected individuals either remain asymptomatic or recover rapidly with only minimal symptoms, and plasma from these convalescent patients usually contains nAbs [4, 5] . Second, transfer of plasma containing nAbs from convalescent patients to symptomatic patients has been beneficial in some cases [6] [7] [8] . Third, recombinant nAbs that inhibit the interaction between SARS-CoV-2 and host cells confer protection in cell-based assays and animal models [9, 10] , and efficacy has been observed for nAbs targeting related coronaviruses SARS-CoV [11] [12] [13] and MERS [14] . Consequently, a number of nAbs have entered clinical trials as post-infection treatment of COVID-19 associated with SARS-CoV-2 (Clinicaltrials.gov -NCT04452318, NCT04497987), with some (Bamlanivimab, Casirivimab, and Imdevimab) receiving Emergency Use Authorization for treatment of mildly ill subjects.

SARS-CoV-2 virions contain 25-100 glycosylated spike (S) proteins that protrude from the viral membrane [15, 16] . The S-protein binds to the host cell receptor, angiotensin-converting enzyme 2 (ACE2), to mediate viral entry [17] . The S-protein is a homotrimer and each of its three receptor binding domains (RBD) can be found in either the "up" or the "down" conformation, the former required for ACE2 binding. The most potent nAbs against both SARS-CoV-2 and SARS-CoV bind to the RBD and sterically block its interaction with ACE2 [18] [19] [20] [21] [22] .

Consequently, we focused our efforts on developing nAbs that bound to the RBD and competed with ACE2.

To date, all clinically advanced candidate nAbs against SARS-CoV-2 infection have been derived by cloning from B cells of recovered COVID-19 patients or from other natural sources [10, 18, [20] [21] [22] [23] [24] . Here, we applied an alternative strategy using in vitro selection with phage-displayed libraries of synthetic Abs built on a single human IgG framework derived from a clinically validated drug, trastuzumab [25] . This approach enabled rapid production of high affinity nAbs with drug-like properties ready for pre-clinical assessment. Moreover, the use of a highly stable framework enabled facile and modular design of ultra-high-affinity nAbs in tetravalent formats that retained favorable drug-like properties while exhibiting neutralization potencies that greatly exceeded those of the bivalent IgG format. Our tetravalent platform provides a general approach for rapidly improving the potency of virtually any nAb targeting pathogen-related, receptor-binding proteins, including SARS-CoV-2 and related coronaviruses and while improving existing COVID-19 nAb drugs, can be adapted in response to resistant mutations or to future viral threats.

Using a phage-displayed human antigen-binding fragment (Fab) library similar to library F [26] , we performed four rounds of selection for binding to the biotinylated RBD of the Sprotein of SARS-CoV-2 immobilized on streptavidin-coated plates. Screening of 384 Fab-phage clones revealed 348 that bound to the RBD but not to streptavidin. The Fab-phage were screened by ELISA and those exhibiting >50% loss of binding to the RBD in the presence of 200 nM ACE2 were sequenced, resulting in 34 unique clones (Fig. 1A) that were converted into the full-length human IgG1 format for purification and functional characterization.

To determine relative binding strength, ELISAs were performed with serial dilutions of IgG protein binding to streptavidin-captured, biotinylated S-protein trimer. These assays showed that three IgGs bound with sub-nanomolar EC50 values (Fig. 1B, C and Table 1 ). Each IgG also partially blocked the binding of biotinylated ACE2 to immobilized S-protein (Fig. 1D) . Moreover, similar to the clinical benchmark IgG trastuzumab, these three IgGs did not bind to seven immobilized, heterologous proteins whose promiscuous interaction with some IgGs can be predictive of poor pharmacokinetics in vivo (Fig. 1E) [27, 28] . We also used biolayer interferometry (BLI) to measure binding kinetics and to determine avidities more accurately. All three antibodies exhibited sub-nanomolar KD apparent (Table 1) , in agreement with estimates determined by ELISA (Fig. 1C) . Among these, IgG 15033 exhibited the highest avidity, which was mainly due to a two-or seven-fold higher on-rate than IgG 15031 or 15032, respectively.

Based on the binding kinetics, we focused further efforts on Ab 15033.

We took advantage of the modular design principles of our synthetic Ab library to improve the affinity of Ab 15033. The naïve library was constructed with tailored diversification of key positions in all three heavy chain complementarity-determining regions (CDRs) and the third CDR of the light chain (CDR-L3). We reasoned that the already high affinity of Ab 15033 could be further improved by recombining the heavy chain with a library of light chains with naïve diversity in CDR-L3. Following selection for RBD binding, the light chain library yielded numerous variants, of which 17 were purified in the IgG format and analyzed by BLI. Several of the variant light chains resulted in IgGs with improved binding kinetics compared with IgG 15033, and in particular, IgG 15033-7 (Fig. 1B) exhibited significantly improved avidity (KD apparent = 300 pM for 15033 or 39 pM for 15033-7) due to an off-rate that was an order of magnitude slower (Table 1) .

To rationalize the molecular basis for the differences between nAbs 15033 and 15033-7, and confirm blockade of ACE2 binding, we first solved the X-ray crystal structures of Fabs in complex with the SARS-CoV-2 RBD at 3.2 and 3.0 Å resolution, respectively ( Fig. 2A , Table   S1 ). As expected, backbone superposition showed that the two complexes were essentially identical (RMSD = 0.17 Å). The binding of Fab 15033-7 to the RBD resulted in an interface with 1130 and 1112 Å 2 of buried surface area on the RBD and Fab, respectively. Of the surface area buried on the Fab, 59% comes from the light chain and 41% from the heavy chain, with the Fab paratope centered on the receptor binding motif of the RBD (Fig. 2B) . The contributions of individual CDR loops to RBD binding are detailed in Table S2 . Comparison of the Fab and ACE2 footprints on the RBD revealed that they overlap extensively, with 69% of the ACE2 footprint covered by that of the Fab footprint (Fig. 2C) . It follows that direct steric hindrance explains the ability of 15033 and 15033-7 to block the RBD-ACE2 interaction (Fig. 1D) .

Fabs 15033 and 15033-7 recognize a patch of surface-exposed non-polar residues on the RBD using several non-polar residues in both their heavy and light chain CDRs (Fig. 2D) .

The significance of this interaction mode is made clear by a comparison with the ACE2-RBD complex (Fig. 2E) . The same patch of non-polar RBD residues mediates the interaction with ACE2, a reflection of their importance in both the Fab-RBD and ACE2-RBD complexes. The RBD of SARS-CoV-2 binds to ACE2 with high affinity and exploiting this surface on the RBD may explain why Ab 15033 emerged as the most potent Ab from our initial screens. RBD residue Phe 486 is particularly noteworthy as its side chain is completely buried in a pocket between CDRs H2, H3 and L3.

Abs 15033 and 15033-7 differ at only two positions (15033, Tyr108L/Arg109L; 15033-7, His108L/Thr109L). In the RBD-15033 complex, Tyr 108L makes van der Waals interactions with RBD residues Tyr 473 and Ala 475 , as well as a weak hydrogen bond to the side chain of Tyr 473 (Fig. 2F) . In the higher affinity RBD-15033-7 complex, the side chain of the equivalent residue, His 108L , makes similar interactions. However, its side chain also makes an additional intramolecular hydrogen bond to the corresponding residue, Thr 109L , the other residue that differs between 15033 and 15033-7. Taken together, these residue changes likely stabilize the 15033-7 CDR-L3 loop conformation with a concomitant improvement in both the van der Waals and hydrogen bond interactions with RBD residues Tyr 473 and Ala 475 .

Using electron cryo-microscopy (cryo-EM), we also determined the structure of Fab 15033-7 in complex with the S-protein trimer (Table S3) . This analysis resulted in the identification of at least 4 different complexes with either two or three Fabs bound to each Sprotein trimer (Fig. 3, S1, S2) . For all but one of the Fabs in these complexes, interpretable density for the entire Fab was observed, a result of Fab-Fab interactions that served to immobilize the Fab and the RBD to which it was bound.

In two of the complexes with three Fabs bound (Fig. 3A,B) , all three RBDs were found in the "up" conformation. The Fabs were relatively well-ordered in both complexes, as adjacent Fabs contacted each other around the three-fold rotation axis describing the S-protein trimer.

Although three-fold symmetry was observed in one of the complexes (Fig. 3A, S1A) , in the other, one of the Fab-RBD units made unique Fab-Fab interactions that broke the symmetry ( Fig. 3B, S1B ).

In the third complex with three Fabs bound, two of the RBDs were in the "up" conformation and the third RBD was in the "down" conformation ( Fig. 3C, S1C) . To accommodate the latter, one of the other Fab-RBD units was pushed away from the 3-fold rotation axis where it was unable to make Fab-Fab contacts. As such, the density for the Fab was relatively weak, an indication of motion/disorder. The remaining Fab-RBD unit stacked over the one in the "down" conformation, making extensive and yet again different Fab-Fab contacts.

This led to a well-packed arrangement where the Fab bound to the "down" RBD was sandwiched between the two "up" RBDs.

In the complex with 2 Fabs bound (Fig. 3D, S1D) , the bound RBDs were in the "up" conformation and the Fab-Fab interactions were very similar to those found in the symmetrical complex with three Fabs bound (Fig. 3A, S1A) . The structure showed that the unbound RBD, which was in the "down" conformation, could not sterically accommodate a Fab and further affirmed that one of the two "up" Fab-RBD units must move away from the 3-fold rotation axis if binding to it was to occur.

Analysis of the distances between the C-termini of the heavy chains of the Fabs in these complexes showed that they range from 45 to 120 Å (Fig. 3 , lower row). In some cases, they are oriented such that two of them, with some repositioning of the Fab-RBD unit, could be linked to a single IgG molecule. Indeed, as described below, negative stain electron microscopy (nsEM) confirmed simultaneous binding of both Fab arms of a single IgG 15033-7 molecule to the S-protein trimer.

Taken together, our structural analysis showed that Fab 15033/15033-7 blocks ACE2 binding to the RBD by direct steric hindrance and that simultaneous binding of both IgG arms to the S-protein trimer likely enhances potency through avidity effects. It also showed that Fab 15033/15033-7 can make four conformationally distinct complexes with the S-protein trimer through interactions involving the RBD in either the "up" or "down" conformation, a property also shared by some other ACE2-blocking Fabs [29] . While it was not immediately apparent why these Fabs were able to recognize both "up" and "down" positions, such flexibility bodes well for efforts aimed at the design of improved antibody-based therapeutics. Finally, it showed that different Fab-Fab interaction modes served to define and stabilize the complexes observed.

Building on these observations, we explored whether we could further enhance the interactions of these nAbs with the S-protein trimer using modular design strategies. We generated tetravalent versions of 15033 and 15033-7 by fusing additional copies of the Fab to either the N-or C-terminus of the IgG heavy chain to construct molecules that we termed Fab-IgG or IgG-Fab, respectively (Fig. 4A) .

Our ultimate goal is to produce nAbs that can be used to counter SARS-CoV-2 infections either as a therapeutic and/or as a prophylactic. Aside from high affinity and specificity, effective nAb drugs must also possess favorable properties including high yields from recombinant expression in mammalian cells, high thermodynamic stability, and the lack of aggregation and excessive hydrophobic surface area. To examine these properties, we Table 1 , Fig. S3 ). Size exclusion chromatography revealed that each IgG eluted as a predominantly (91 to >95%) monodisperse peak with elution volumes nearly identical to trastuzumab ( Fig. 4B and Table 1 ). Tetravalent molecules eluted as single peaks in advance of trastuzumab, consistent with their larger molecular weights. We also showed that the IgG and tetravalent versions of both 15033 and 15033-7 could be purified to near homogeneity by protein-A affinity chromatography as evidenced by SDS-PAGE (Fig. 4C) .

Taken together, these analyses demonstrated that the IgGs and their tetravalent derivatives possess excellent biophysical properties that will facilitate drug development and production at large scale. Importantly, the tetravalent Abs exhibited greatly reduced off-rates compared with their bivalent IgG counterparts, with KD apparent for the S-protein trimer in the low single-digit picomolar range as measured by BLI (Fig. 4D, Table 1 ). Negative stain micrographs (Fig. 5A) and 2D class averages of IgG 15033-7 and its tetravalent formats (Fig. 5B) provided insights in to modular structure of these antibodies. nsEM of IgG 15033-7, in complex with the S-protein trimer, showed that the two arms of a single IgG bound the S-protein trimer in a pincer-like fashion (Fig. 5C,E) . Fab-IgG 15033-7 also makes pincer-like interactions with a single Sprotein trimer (Fig. 5D,F, Fig. S6, S7) , but the complexes revealed additional density that differed from those observed for the complex of the S-protein trimer with the IgG. In particular, we observed density consistent with that from an additional Fab in the Fab-IgG complexes, suggesting that all three of the S-protein RBDs are bound by Fabs from a single tetravalent nAb molecule, Fab-IgG in this instance. Given the range of complexes observed in our cryo-EM analysis, it is possible that the Fab-IgG, with four available Fabs, can engage all three RBDs within a single S-protein molecule (Fig. 5F ). Further analysis will be required to fully establish whether this occurs, potentially explaining the decreased off-rates shown by the tetravalent proteins due to avidity. Nevertheless, it is clear that both the Fab-IgG and IgG-Fab possess an increased potential for multivalent interactions with one or more S-protein trimers. The latter mode of interaction may be possible on the viral surface and likely contributes to enhanced potency observed for the tetravalent IgGs, as shown below using a cell-based infectivity assay.

We assessed the effects of the Abs on virus infection in an assay that measured the infection of ACE2-expressing Vero E6 cells with the SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2020. All three high affinity nAbs (15031, 15032 and 15033) from the naïve library ( Fig. 1 Table 1 ). The optimized IgG 15033-7 also exhibited high neutralizing potency with an IC50 of 550 pM and its tetravalent Fab-IgG and IgG-Fab versions exhibited the best potencies of all the molecules tested with IC50 values of 60 and 37 pM, respectively. Taken together, these results support the ability of naïve synthetic Ab libraries to yield highly potent nAbs with drug-like properties. Moreover, optimization via engineering of tetravalent formats can produce drug-like molecules with ultrahigh potencies, exceeding those of bivalent IgGs.

To explore the sensitivity of our nAbs to potential escape mutants, we generated HIVgag-based, lentivirus-like particles (VLPs) pseudotyped with the SARS-CoV-2 S-protein. We confirmed ACE2-dependent infection of HEK-293 cells stably over-expressing exogenous ACE2 by pseudotyped VLPs, and that infection was inhibited by either Fc-tagged RBD (RBD-Fc) or IgG 15033 (data not shown). Using this system, we generated a panel of 44 pseudotyped VLP variants (Fig. S5A) , each containing a single alanine substitution at an RBD position within or close to the ACE2-binding site. Fifteen of these VLP variants exhibited a >4-fold reduction in infection compared with the wild-type (wt) VLP, suggesting that the substituted residues contributed favorably to interactions between the RBD and ACE2, and were excluded from further analysis. The remaining 29 VLP variants infected with high efficiency, suggesting that these are positions where residue changes could abrogate antibody binding without affecting the ACE2 interaction.

Using the panel of 29 infective VLP variants, we measured VLP infection after treatment with the various nAbs (Fig. 6B) . We defined as escape mutants those VLP variants for which entry in the presence of 50 nM nAb was >5% of the entry in the absence of the nAb. Based on this definition, we found that 7 of the variants were able to escape from IgG 15033 (Fig. 6B,   S5A ), whereas only 4 could escape from IgG 15033-7. We also found that 15033 in tetravalent Ab format neutralized more variants than it did as an IgG, and that, remarkably, tetravalent Ab 15033-7 strongly neutralized all of the variants but one (Phe 486 ). As discussed above, RBD residue Phe 486 is found in the non-polar interface between the RBD and the Fab and it makes numerous contacts with CDRs H2, H3 and L3, sitting deep in a pocket formed by these contacts (Fig. S5B,C) . As such, it represents a bona fide positional vulnerability where mutant viruses still capable of binding ACE2 could evade neutralization by nAb 15033-7. Comprehensive maps of escape mutations confirm the vulnerability of other nAbs to this mutation, but also suggest strategies by which escape can be overcome with nAb cocktails or bi-specific nAbs [30] .

Overall, these results showed that for IgGs, increasing the affinity of the Fab-RBD interaction increased neutralizing potency and resistance to mutation, and moreover, that tetravalent presentation of the Fab provides even greater potency and resistance to potential escape mutants.

Recently, variants of SARS-CoV2 with enhanced transmissibility have emerged [31] [32] [33] and have been shown to possess mutations within the RBD that could potentially reduce the efficacy of neutralizing antibodies that target this region of the S-protein [34, 35] . In particular, the B.1.351 variant possesses three mutations within the RBD (K417N / E484K / N501Y), which have been shown to increase resistance to therapeutic antibodies, convalescent plasma and vaccine sera [34, 35] . Notably, the E484K mutation alone reduces the inhibitory activity of many neutralizing antibodies that target the RBD [34] .

To assess and compare the in vitro neutralization activities of 15033-7 IgG, its tetravalent formats, and approved therapeutic nAbs (REGN10933 and LY-CoV555) -versus the dominant D614G and emerging B.1.351 variants -we conducted cell-based neutralization assays (described above) using isogenic S-protein variants in the background of the Washington strain of the virus [34] . These assays clearly showed that all three IgGs possessed similar potencies against the D614G variant, while both IgGs 15033-7 and REGN10933 suffered significant loss of potency against the B.1.351 variant, and neutralization by Ly-CoV555 IgG was completely abrogated (Fig. 6C) . In contrast with the bivalent IgGs, the tetravalent 15033-7 nAbs showed enhanced potency against the D614G variant and were also reasonably potent against the B.1.351 variant. This confirms a key point: improved potency obtained through avidity effects upon conversion to tetravalent formats renders nAbs less sensitive to mutations that have emerged since isolation of the original lead nAbs. This further suggests that tetravalent nAbs may also offer enhanced efficacy against variants that have yet to emerge, highlighting a major advantage of this approach.

SARS-CoV-2 has wreaked havoc on global health and the economy, highlighting the need for drug development technologies to combat not only COVID-19, but emerging infectious diseases in general. In this context, we have used synthetic antibody engineering to rapidly develop unique formats of human nAbs as therapeutic candidates. Our nAb formats include natural bivalent IgGs as well as ultra-potent tetravalent molecules arising from a modular design strategy that adds two additional Fabs to the canonical IgG molecule. Importantly, we have shown that enhanced avidities and potencies characteristic of the tetravalent nAbs are achieved without compromising the favorable properties (e.g. yield, solubility, and stability) that make IgG molecules ideal drugs. Moreover, we showed that tetravalent nAbs exhibit enhanced potency against emerging variants of concern and potential virus escape mutants that may yet emerge, a property that highlights the utility of these molecules as therapeutics against SARS-CoV-2 and other viruses capable of mutational escape.

Structural analyses showed that IgG and Fab-IgG 15033-7 make pincer-like interactions with a single SARS-CoV-2 S-protein trimer, an observation providing insight into the basis for the avidity observed for these molecules. It also provides strong evidence that the tetravalent Fab-IgG can engage all three RBDs of the S-protein trimer, and that the RBD can be bound by a Fab in either the "up" or "down" conformation. We did not optimize the tetravalent formats; their very high avidities arose naturally from the geometry of the Fab-RBD complex, the spatial relationships between the Fabs, the flexibility of the RBDs on the S-protein trimer, and fortuitous Fab-Fab interactions that clearly stabilized the complexes observed. We and others have generated many additional Fabs that can inhibit the virus but employ different epitopes to do so, and incorporating these Fabs into tetravalent frameworks, including bispecific formats targeting two distinct epitopes, has the potential to generate a vast array of ultra-high affinity nAbs with minimal further effort. Taken together, these observations underscore the enormous potential of our modular design approach for the development of novel and highly effective nAb therapeutics, including the potential to further optimize even currently approved COVID-19 nAb therapeutics.

COVID-19 has also exposed the need for drug development to respond to emerging viral threats in real time. In this regard, isolation of nAbs from the B cells of infected individuals has emerged as a rapid approach to obtaining leads for drug development. Indeed, several reports have shown that these technologies can deliver drug-grade therapeutic nAbs for manufacturing and subsequent clinical trials in approximately six months [18, 36] . Further highlighting the urgent need and the rapid speed at which drug development has proceeded, these IgG-based nAbs have received emergency-use approval from the US FDA as both cocktail and single agent, and these extraordinarily rapid drug development timelines set a benchmark for alternative technologies. The potencies of other anti-SARS CoV-2 nAbs obtained in similar fashion range from nanomolar [37] to picomolar [38] , but those that have been awarded approval for emergency use have potencies in the middle of this range [18, 39] . Thus, it is worth noting that antibodies with higher in vitro potencies may further improve in vivo efficacy, and conversion to tetravalent formats may enhance potency of nAbs in general.

With our platform, we show that synthetic in vitro Ab engineering is comparable to B cell cloning, in terms of both speed and potency of drug development [18, 40] . Our project was initiated at the beginning of April 2020 with the identification of our first naïve Ab leads. Within a month, we validated lead IgG molecules as neutralizing agents in cell-based assays with authentic virus. In parallel, we initiated further selections to optimize the Fab 15033 paratope, that yielded our best lead nAb 15033-7; both Fabs were then reformatted as tetravalent molecules (Fab-IgG and IgG-Fab) to further enhance potency. Though others have now shown enhanced potency of SARS-CoV-2 neutralization with oligomers of Ab variable domains [41] and synthetic proteins [42] , insofar as our format closely resembles natural Abs, they can also be manufactured at large scale, possess long half-lives and likely exhibit low immunogenicity, all of which are required of effective drugs. Indeed, by the beginning of October, we established manufacturing-grade stable mammalian cells capable of producing multi-gram quantities of drug-grade nAbs from a litre of culture, in both the IgG and tetravalent formats. Thus, synthetic Ab engineering technologies can match the six-month lead-to-manufacture timelines established by methods based on the cloning of natural nAbs.

Our synthetic engineering technologies offer exquisite control over Ab design, and by introducing tailored diversity into an optimized IgG framework, ensure that candidate therapeutics possess biophysical properties that are ideal for drug development. Facilitated by the use of highly stable frameworks, we have demonstrated the rapid construction of complex tetravalent formats that enhance potency while retaining favorable drug-like properties. To minimize risk of genicity, we chose as a framework the highly validated drug trastuzumab, which has been well tolerated with minimal immunogenicity in thousands of breast cancer patients [43] , and we incorporated synthetic diversity that was designed to mimic natural diversity at only the most hypervariable positions in the CDRs [44] . Perhaps most importantly, synthetic methods do not rely on infected patients (i.e. natural repertoires) as a source of drug leads. By its very nature, B cell cloning is a reactive technology that can be implemented only after a viral outbreak, placing limitations on drug development response times. With synthetic in vitro methods, drug development can be undertaken in a proactive manner, enabling development and stockpiling of potential therapeutics in advance of outbreaks. Indeed, large-scale surveillance and sequencing efforts have provided unprecedented access to the genomes of numerous SARS-CoV-2-related viruses and other pathogens with the potential to cross species barriers and infect humans [45, 46] . With our approach, it is feasible to develop -in advance and in parallel -synthetic Abs against hundreds of antigens [47] , and working within a collaborative international network, we have initiated efforts with this aim.

This study was supported in part by contracts and grants from NIH (R01 AI157155) and 15034 15035 15036 15037 15038 15039 15040 15041 15042 15043 15044 15045 15046 15047 15048 15049 15050 15051 15052 15053 15054 15055 15056 15057 15058 15059 15060 15061 15062 15063 

A -S F H Y Y Y G F 15033 S V S S A S A S S Y R Y P I L G G Y S Y Y Y G ---------G F G M 15033-7 S V S S A S A S S T Y P I L G G Y

I Y A S G G A T I Y A S G G A T S Y Y G ---------G F G M Y B S S Figure 1 H D Y G F D Q 27 Q Q Q G F D G F D G F D 29 28 27 106 105 A R A R A R A R D Y D Y D Y

Mammalian cells were maintained in humidified environments at 37 °C in 5% CO2 in the indicated media. Vero E6 (ATCC), HEK293T (ATCC) and HEK293T cells stably overexpressing ACE2 were maintained at 37 °C in 5% CO2 in DMEM containing 10% (vol/vol) FBS. Expi293F cells (ThermoFisher) were maintained at 37 °C in 8% CO2 in Expi293F expression media (ThermoFisher).

The previously reported piggyBac transposase-based expression plasmid PB-T-PAF [49] containing a CMV promotor (PB-CMV) and a woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) was used for large-scale transient expression. cDNA encoding the SARS-CoV-2 S-protein ectodomain trimer (residues 1-1211), followed by a foldon trimerization motif [50] , a 6xHis tag and an AviTag biotinylation motif [51] was cloned in to the PB-CMV vector using standard molecular biology techniques, and residues 682-685 (RRAR) and 986-987 (KV) were mutated to SSAS or PP sequences, respectively, to remove the furin cleavage site on the SARS-CoV-2 spike protein or to stabilize the pre-fusion form of the spike [52] , respectively. The SARS-CoV-2 receptor binding domain (RBD, residues 328-528), the soluble human ACE2 construct (residues 19-615), and the SARS-CoV RBD (residues 315-514), each followed by a 6xHis tag and an AviTag, were similarly cloned into the same vector. For expression, PB-CMV expression constructs were mixed with Opti-MEM media (Gibco) containing 293fectin reagent (Thermo Fisher) and the mixture was incubated for 5 min before addition to the shaker flask containing 10 6 Freestyle 293-F cells/mL grown in suspension in Freestyle 293 expression media (Thermo Fisher). Expression was allowed to continue for 6 days before purification.

Expressed proteins were harvested from expression medium by binding to Ni-NTA affinity resin 

A synthetic, phage-displayed antibody library [26] was selected for binding to SARS-CoV-2 RBD in solution. In each round, phage library was first depleted on neutravidin immobilized in wells of a 96-well Maxisorp plate from a 2 µg/mL solution incubated with shaking overnight at 4 o C, then incubated with 50 nM biotinylated RBD in solution for two hours at RT. Protein-phage complexes were captured in wells coated with neutravidin as above for 15 min at RT. After washing with 1X PBS pH 7.4 containing 0.05% Tween, phage were eluted for 5 min with 0.1 M HCl and then neutralized with 1 M Tris pH 8.0. Eluted phage were amplified, purified, and selected for binding to target for a total of 5 rounds, after which, individual phage clones were subjected to DNA sequencing, as described [26] .

For ELISAs, plates were coated with neutravidin, as above, then blocked with PBS, 0.2% BSA for 1 h. Biotinylated target protein was captured from solution by incubation in neutravidincoated and BSA-blocked wells for 15 min with shaking at RT, and subsequently, phage or Ab was added and allowed to bind for 30 min. Plates were washed, incubated with an appropriate secondary antibody, and developed with TMB substrate as described [53] .

DNA fragments encoding heavy chain Fab regions (VH-CH1; terminating at hinge residue Thr 10 , IMGT numbering [48] ) were amplified by PCR from the IgG expression constructs. Tetravalent Ab constructs were generated by fusing these fragments with their respective IgG heavy chain in the pSCSTa mammalian expression vector using Gibson assembly (New England Biolabs, Ipswich, MA). Fab-IgG constructs were arranged by fusing a heavy chain Fab domain to the Nterminus of the IgG using a S(G4S)3 linker. IgG-Fab constructs were arranged by fusing a heavy chain Fab domain to the C-terminus using a G(G4S)2GGGTG linker. For both formats, the Fc region terminated at Gly 129 (IMGT numbering [48] ).

IgG and tetravalent Abs were produced in Expi293F cells (ThermoFisher) by transient transfection, by diluting heavy and light chain construct DNA in OptiMem serum-free media (Gibco) before the addition of and incubation with FectoPro (Polyplus Transfection) for 10 min.

For IgG expression, equivalent amounts of plasmids encoding heavy chain or light chain were transfected, whereas for tetravalent formats, a ratio of 2:1 light chain to heavy chain plasmids was used. Following addition of the DNA complex to Expi293F cells and a 5-day expression period, Abs were purified using rProtein A Sepharose (GE Healthcare), then buffer exchanged and concentrated using Amicon Ultra-15 Centrifugal Filter devices (Millipore). IgGs were stored in PBS (Gibco), and tetravalent Abs were stored in 10 mM L-Histidine, 0.9% sucrose, 140 mM NaCl, pH 6.0.

Protein samples (50 g) were injected onto a TSKgel BioAssist G3SWxl column (Tosoh) fitted with a guard column using an NGC chromatography system and a C96 autosampler (Biorad).

The column was preequilibrated in a PBS mobile phase and protein retention was monitored by absorbance at 215 nm during a 1.5 CV isocratic elution in PBS.

The binding kinetics and estimation of apparent affinity (KD) of Abs binding to the S-protein were determined by BLI with an Octet HTX instrument (ForteBio) at 1000 rpm and 25 o C. Biotinylated S-protein was first captured on streptavidin biosensors from a 2 µg/mL solution to achieve a binding response of 0.4-0.6 nm and unoccupied sites were quenched with 100 µg/mL biotin.

Abs were diluted with assay buffer (PBS, 1% BSA, 0.05% Tween 20) and 67 nM of an unrelated biotinylated protein of similar size was used as negative control. Following equilibration with assay buffer, loaded biosensors were dipped for 600 s into wells containing 3-fold serial dilutions of each Ab starting at 67 nM, and subsequently, were transferred back into assay buffer for 600 s. Binding response data were corrected by subtraction of response from a reference and were fitted with a 1:1 binding model using ForteBio's Octet Systems software 9.0.

Thermostabilities of Abs were determined by differential scanning fluorimetry using Sypro

Orange, as described [54] , with a 1 µM solution of Ab and temperature range from 25-100 o C in 0.5 o C increments. 

The SARS-CoV-2 RBD (residues 328-528) was expressed with a C-terminal 6xHis tag from HEK293F GnT1-minus cells. The Fabs were expressed from HEK293F cells. The RBD was purified from the expression media by metal-affinity chromatography using Ni-NTA beads (Qiagen). The Fab fragments were purified from the expression media using rProtein A Sepharose Fast Flow beads (GE healthcare). The RBD was treated with endoglycosidase H [57] and Carboxypeptidase A (Sigma-Aldrich), to remove the N-glycans and the C-terminal 6xHis tag. The RBD and Fabs were further purified by ion-exchange and hydrophobic interaction chromatography. Before crystallization, the RBD-Fab complexes were purified using size-exclusion chromatography on a Superdex 200 Increase column (GE Healthcare). For both Fab 15033 and Fab 15033-7, the optimized crystallization conditions contained 1.2-1.6 M (NH4)2SO4 and 8-18% glycerol. X-ray diffraction data were collected at 100 K on beamline 08IB-1 at the Canadian Light Source. The diffraction data were integrated and scaled using the XDS package [58] . The structures were solved by molecular replacement using the program Phaser [59] . A homology model of the VH-VL region was produced by the SysImm Repertoire Builder server (https://sysimm.org/rep_builder) [60] . The CDR loops were then deleted from this VH-VL model. The constant (CH1-CL) region search model and the RBD search model were both derived from PDB entry 6W41 [56] . The three models were used to solve the structure by molecular replacement. The atomic models were built using Coot [61] and refined with Phenix.refine [62] .

3 µL of the S-protein ectodomain were applied to the surface of a glow-discharged (60 s, 15 mA), carbon-coated copper mesh grid. The grid was washed with water and stained with 3 µL of 2% uranyl formate. Micrographs were acquired on a Talos L120C 120 kV electron microscope equipped with a Ceta 16M CMOS camera. Particle selection and two-dimensional classification were carried out using cryoSPARC v2. Contrast transfer function (CTF) estimation was performed using GCTF [63] .

Four additional substitutions for proline residues (817P/A892P/A899P/A942P) were introduced to the S-2P SARS-CoV-2 S-protein ectodomain to stabilize the prefusion conformation [64] . Fab 15033-7 was mixed with the SARS-CoV-2 spike ectodomain at a 3:1 molar ratio. 3 µL of the Fab-spike mixture containing 0.4 mg/mL total protein were applied to a glow-discharged (60 s, 15 mA) C-flat 2/2 carbon holey grid (CF-2/2-4C, Electron Microscopy Science). Plunge vitrification was performed using a Thermo Fisher Scientific Vitrobot Mark IV instrument. The grids were blotted for 2.5 s at 100% humidity and 277 K before being plungefrozen in liquid ethane cooled to 90 K. Specimen screening and optimization were performed using a Talos L120C 120 kV electron microscope equipped with a Ceta 16M CMOS camera.

High-resolution data were collected on a Thermo Fisher Scientific Titan Krios G3 300 kV microscope equipped with a Falcon 4 Direct Electron Detector. The data were collected at 75000x nominal magnification, resulting in a calibrated pixel size of 1.03 Å. Each movie was recorded in counting mode with a 10 s exposure and saved in 30 fractions. The total exposure was 38 electrons per Å 2 . The data were collected with a 1.0-2.2 µm defocus setting. A total of ~6431 movies were collected for the final high-resolution dataset.

Full-frame motion and local motion corrections of the cryo-EM movies were performed using implementations of the alignframes_lmbfgs algorithm [65] in cryoSPARC v2 [66] . CTF parameters were estimated using GCTF [63] . Particle selection was initially performed using a Gaussian blob picker, then by Topaz neural network picking [67] , both in cryoSPARC v2. Twodimensional classification of the particle images was performed using cryoSPARC v2. The particle images corresponding to Fab-S-protein complexes in the different conformations were separated by performing heterogenous refinement in cryoSPARC v2. Initial map generation and homogenous, heterogenous and non-uniform three-dimensional refinements were performed in cryoSPARC v2. For the map with three RBDs in the up conformation, the three-dimensional refinements were carried out with either C1 or C3 symmetry imposed. The maps generated with C3 symmetry were used for model building. A previously reported SARS-CoV-2 spike structure, PDB entry 6VXX [68] , and the 15033-7:RBD complex reported here, were first docked into the map using UCSF Chimera [69] and then manually modified using Coot [70] . The HV-LV and HC1-LC domains of the Fab were docked individually to account for elbow angle differences (SI Figure ZFH ). The resulting model was refined with C3 symmetry against the cryo-EM map using Rosetta [71] and Phenix [72] . The resulting C3-symmetric model was used as starting model to build the other three structures, which were also refined against the corresponding cryo-EM maps using Rosetta and Phenix. The atomic models were validated using Molprobity [73] and the comprehensive validation (cryo-EM) tool in Phenix [72] . To improve the interpretability of the Fab-RBD interaction, local refinement of the Fab-RBD unit was performed in cryoSPARC v2 using a mask encompassing one of the Fab-RBD units in the C3-symmetric structure. Moderate resolution improvement for the Fab-RBD unit was achieved ( Fig. S2H) .

The crystal structures of the RBD-Fab 15033 and RBD-Fab 15033-7 complexes were deposited in the PDB with accession codes 7KLG and 7KLH, respectively. The S-protein-Fab 15033-7 cryo-EM maps and structures were deposited to EMDB and PDB with the following accession codes: EMD-22925/PDB:7KMK (2 Fab bound, 2-"up"-1-"down"), EMD-22926/PDB:7KML (3 Fab bound, 3-"up", C3-symmetric), EMD-23064/PDB:7KXJ (3 Fab bound, 3-"up" asymmetric), EMD-23065/PDB:7KXK (3 Fab bound, 2-"up", 1-"down").

Supplementary Information is available for this paper. Table S1 . X-ray data collection and refinement statistics Table S2 . Contributions of the 15033-7 CDR loops to RBD binding Table S3 . Cryo-EM data collection and image processing Fabs (colored ribbons) are shown in the cryo-EM maps for each of the four structures: A) the 3-Fab-bound, 3-"up", C3 symmetric structure; B) the 3-Fab-bound, 3-"up", asymmetric structure; C) the 3-Fab-bound, 2-"up"-1-"down" structure; "A", "B" and "C" label the three Fab-RBD units where "C" is in the "down" conformation, "A" stacks over "C" and "B" is the Fab-RBD unit pushed away from the 3-fold rotation axis; D) the 2-Fab-bound, 2-"up" structure; E) A top view of the "B" Fab-RBD unit (Fab, orange; RBD, green) shown in C). F) Comparison of the 15033-7

Fab-RBD unit found in the C3 symmetric cryo-EM structure (Fab, blue; RBD, green) with that found in the crystal structure (Fab and RBD, gray). A change in the Fab elbow angle is  Rapid isolation of neutralizing antibodies without natural immune repertoires  Facile re-reformatting to tetravalent antibodies enhances potency  Tetravalent antibodies possess drug-like yields, stability and specificity  Structural characterization reveals multiple modes of S-protein binding  Tetravalent formats also enhance antibody resistance to mutational escape 

☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Remdesivir for the Treatment of Covid-19 -Preliminary Report

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates, The Lancet

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Effect of Convalescent Plasma Therapy on Time to Clinical

Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

Potent crossreactive neutralization of SARS coronavirus isolates by human monoclonal antibodies

Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets

Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus

SARS-CoV-2 structure and replication characterized by in situ cryo-electron tomography

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection

A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes

Broad neutralization of SARS-related viruses by human monoclonal antibodies

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

CDR-H3 diversity is not required for antigen recognition by synthetic antibodies

Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation

Biophysical properties of the clinical-stage antibody landscape

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein

Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data

Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization

Title: LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Title: LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike

De novo design of picomolar SARS-CoV-2 miniprotein inhibitors

Trastuzumab immunogenicity development in patients' sera and in laboratory animals

CDR-H3 diversity is not required for antigen recognition by synthetic antibodies

A strategy to prevent future epidemics similar to the 2019-nCoV outbreak

A review of studies on animal reservoirs of the SARS coronavirus

A high through-put platform for recombinant antibodies to folded proteins

IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains

Simple piggyBac transposon-based mammalian cell expression system for inducible protein production

Structure of bacteriophage T4 fibritin: a segmented coiled coil and the role of the C-terminal domain

Site-specific biotinylation of purified proteins using BirA

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Structure-Directed and Tailored Diversity Synthetic Antibody Libraries Yield Novel Anti-EGFR Antagonists

Highthroughput screening of formulations to optimize the thermal stability of a therapeutic monoclonal antibody

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Phaser crystallographic software

Repertoire Builder: High-throughput structural modeling of B and T cell receptors, Molecular Systems Design and Engineering

Features and development of Coot

Towards automated crystallographic structure refinement with phenix.refine

Gctf: Real-time CTF determination and correction

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Alignment of cryo-EM movies of individual particles by optimization of image translations

CryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination

Positiveunlabeled convolutional neural networks for particle picking in cryo-electron micrographs

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

UCSF Chimera -A visualization system for exploratory research and analysis

Coot: Model-building tools for molecular graphics

Automated structure refinement of macromolecular assemblies from cryo-EM maps using Rosetta

Macromolecular structure determination using X-rays, neutrons and electrons: Recent developments in Phenix

MolProbity: More and better reference data for improved all-atom structure validation